KMKazuhiko Morii

Kazuhiko Morii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kazuhiko Morii has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroaki Okushin

    Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan

    12 shared publications
  • Shinichiro Nakamura

    Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan

    11 shared publications
  • Takeharu Yamamoto

    Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan

    11 shared publications
  • Hiroaki Okushin

    Department of Hepatology, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji, Hyogo 670-8540, Japan

    6 shared publications
  • Shiro Yuasa

    Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan

    6 shared publications
  • Koichi Uesaka

    Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan

    5 shared publications

Latest Publications

  • Open Access

    Clinical Outcomes of Next-Generation Microwave Thermosphere Ablation for Hepatocellular Carcinoma with Primarily Hepatitis-Related Etiology

    by Shinichiro Nakamura, Toshifumi Tada, Masahiko Sue, Yu Matsuo, Shiho Murakami, Toshiro Muramatsu, Kazuhiko Morii, Hiroyuki Okada

    Background and aim: We investigated the clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent next-generation microwave thermosphere ablation (MTA). Methods: A total of 429 patients with 607 HCCs (maximum tumor diameter ≤40 mm) were included. We defined the following areas of the liver as those where MTA therapy is difficult to perform: caudate lobe and areas near the primary and secondary branches of the intrahepatic portal vein, inferior vena cava, gallbladder, heart, duodenum, abdominal esophagus, collateral veins around the liver, and spleen. Factors which predisposed patients to local tumor recurrence in the context of tumor location and complications were examined. Results: The primary etiologies of HCC were hepatitis-related: 259 (60.4%) cases of HCV, 31 (7.3%) cases of HBV, and two instances of both. Median maximum tumor diameter was 15.0 (interquartile range, 10.0–21.0) mm. There were 86 tumors in areas of the liver where MTA is difficult. The most common area was near the primary and secondary branches of the intrahepatic portal vein (26 nodules). The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.4%, 8.0%, and 8.5%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: 6.6%, 13.8%, and 29.4% at three years in the ≤20 mm group (n = 483), 20–30 mm group (n = 107), and ≥30 mm group (n = 17), respectively (p < 0.001). The cumulative local tumor recurrence rate was similar despite difficult-to-treat status (p = 0.169). In the multivariable analysis, tumor size (>15 mm) (hazard ratio [HR], 2.15; 95% confidence interval [CI], 1.11–4.16; p = 0.023) and ablative margin (15 mm) (odds ratio, 3.41 95% CI, 1.53–7.84; p = 0.026) was significantly associated with complications. Conclusions: MTA is a safe and effective local ablation therapy for HCC, even for tumors located in areas of the liver where local ablation therapy is difficult.


  • Open Access

    Clinical Outcomes of Next-Generation Microwave Thermosphere Ablation for Hepatocellular Carcinoma with Primarily Hepatitis-Related Etiology

    by Shinichiro Nakamura, Toshifumi Tada, Masahiko Sue, Yu Matsuo, Shiho Murakami, Toshiro Muramatsu, Kazuhiko Morii, Hiroyuki Okada

    Background and aim We investigated the clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent next-generation microwave thermosphere ablation (MTA). Methods A total of 429 patients with 607 HCCs (maximum tumor diameter ≤40 mm) were included. Results The primary etiologies of HCC were hepatitis-related: 259 (60.4%) cases of HCV, 31 (7.3%) cases of HBV, and two instances of both. Median maximum tumor diameter was 15.0 (interquartile range, 10.0–21.0) mm. There were 86 tumors in areas of the liver where MTA is difficult. The most common area was near the primary and secondary branches of the intrahepatic portal vein (26 nodules). The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.4%, 8.0%, and 8.5%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: ≤20 mm group (n=483), 20–30 mm group (n=107), and ≥30 mm group (n=17) (p<0.001). The cumulative local tumor recurrence rate was similar by difficult-to-treat status (p=0.169). In the multivariable analysis, tumor size (per 1 mm) (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.03–1.11; p<0.001) and ablative margin (per 1 mm) (HR, 0.81; 95% CI, 0.70–0.92; p=0.002) were significantly associated with local tumor recurrence. Only tumor size (per 1 mm) (odds ratio, 1.08; 95% CI, 1.02–1.15; p=0.015) was significantly associated with complications. Conclusions MTA is a safe and effective local ablation therapy for HCC, even for tumors located in areas of the liver where local ablation therapy is difficult.

  • Open Access

    Diffuse Reticulate Purpura

    by Kazuhiko Morii, Rei Okada, Takeharu Yamamoto, Shinichiro Nakamura

    Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies


  • Open Access

    Hepatocellular Carcinoma in a Patient with Hereditary Hemorrhagic Telangiectasia

    by Kazuhiko Morii, Riku Uematsu, Takeharu Yamamoto, Shinichiro Nakamura, Hiroaki Okushin, Noriyuki Nishiwaki, Takanori Watanabe, Kyohei Kai, Shiso Sato

    Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies


  • Open Access

    Streptococcus Anginosus Group-associated Pyogenic Liver Abscess

    by Kazuhiko Morii, Shigeyoshi Fujiwara, Shinichiro Nakamura, Hiroaki Okushin

    Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies


  • Open Access

    Infectious Hepatic Cyst: An Underestimated Complication

    by Kazuhiko Morii, Takeharu Yamamoto, Shinichiro Nakamura, Hiroaki Okushin

    Objective An infectious hepatic cyst (IHC) is a hepatic cyst complicated with secondary infection and is generally assumed to be rare. However, we have experienced no small number of patients with IHC in recent clinical practice. We therefore examined the incidence and clinical characteristics of IHC. Methods The medical records of patients with IHC who were hospitalized at our institution between January 2012 and December 2016 were retrospectively reviewed. Their demographic factors, biochemical, bacteriological, imaging, and treatment results were explored and compared with those of patients with pyogenic liver abscess (PLA). Patients Twelve patients with IHC and 39 with PLA were identified. Results The IHCs were significantly larger in diameters than the PLAs, and patients with IHCs tended to be older and more often women than those with PLAs. IHCs showed characteristic imaging features, including heterogeneous contents with occasional fluid-debris levels, a thickened cystic wall with rim enhancement, perilesional edema and hyperaemia. Patients with IHCs had a significantly shorter hospital stay than those with PLAs. Conclusion Physicians should note that IHCs are not rare. A careful imaging evaluation can suggest an IHC, and the timely aspiration of the content can lead to an accurate diagnosis. The cystic wall may keep the infectious material confined within the IHC, resulting in the observed good treatment outcome with catheter drainage.


  • Open Access

    Multilocular Pyogenic Liver Abscess with Poorly Liquefied Content: A Potential Therapeutic Concern

    by Kazuhiko Morii, Takeharu Yamamoto, Shinichiro Nakamura, Shigeyoshi Fujiwara, Hiroaki Okushin

  • Open Access

    Portal Hypertension Does Not Preclude the Efficacy of Direct-acting Anti-Hepatitis C Viral Therapy

    by Kazuhiko Morii

    Totally, 113 patients were included in this study; 26 with CSPH and 87 without CSPH. HCV genotype 1b-infected patients were treated with either daclatasvir plus asunaprevir or sofosbuvir plus ledipasvir. HCV genotype 2-infected patients were treated with sofosbuvir plus ribavirin. Sustained virological response (SVR) rates were equally good in patients with CSPH (96%) and in those without CSPH (93%). In patients who achieved SVR, prompt improvements in the hepatic function were observed. Recovery was more pronounced in patients with CSPH. There was no early treatment discontinuation and no hepatic decompensation.


  • Increasing incidence of elderly‐onset autoimmune hepatitis

    by Kazuhiko Morii, Yuh Nagano, Takeharu Yamamoto, Shinichiro Nakamura, Hiroaki Okushin

    Aim: Autoimmune hepatitis (AIH) commonly shows bimodal distribution of onset age: at young adulthood and at 50–60 years‐of‐age. However, in recent times, the incidence of elderly‐onset AIH seems to be increasing. This study aimed to investigate whether the incidence of elderly‐onset AIH is increasing, and whether these patients show any clinical features different from those observed in younger patients.Methods: Data about patients with newly diagnosed AIH visiting the Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan, were retrospectively collected for the period ranging from January 2010 to May 2016. A total of 71 patients (56 women and 15 men, age 18–88 years) were included in this study. Patients were divided into two cohorts: elderly (≥70 years; n = 28) and adult cohort (15–69 years; n = 43). Demographic and clinical characteristics, biochemical and serological markers, radiological and histological findings, and therapeutic courses were evaluated.Results: The median age of the patients was 65 years, the most frequent range being the 70s (37%), followed by the 60s (25%). The elderly cohort had significantly higher levels of serum immunoglobulin G and antinuclear antibody, lesser hepatitis activity scores, and lesser chance of developing other autoimmune diseases. They tended to have higher C‐reactive protein levels and lower serum alanine aminotransferase levels. All patients achieved clinical remission after treatment.Conclusions: This study clearly showed an increase in the incidence of elderly‐onset AIH. These patients had some unique characteristics, showing that the development of elderly‐onset AIH is influenced by age‐associated immune dysfunction called immunosenescence. Geriatr Gerontol Int 2017; 17: 1722–1728.


  • Dubin–Johnson Syndrome

    by Kazuhiko Morii, Takeharu Yamamoto

    Images in Clinical Medicine from The New England Journal of Medicine — Dubin–Johnson Syndrome